Connection

ANITA SABICHI to Female

This is a "connection" page, showing publications ANITA SABICHI has written about Female.
Connection Strength

0.102
  1. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila). 2011 Oct; 4(10):1580-9.
    View in: PubMed
    Score: 0.015
  2. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
    View in: PubMed
    Score: 0.011
  3. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin Oncol. 2004 Apr; 31(2 Suppl 7):36-44.
    View in: PubMed
    Score: 0.009
  4. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clin Cancer Res. 2003 Jul; 9(7):2400-5.
    View in: PubMed
    Score: 0.008
  5. Nivolumab Treatment for Cancers in the HIV-infected Population. J Immunother. 2018 Oct; 41(8):379-383.
    View in: PubMed
    Score: 0.006
  6. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst. 1998 Apr 15; 90(8):597-605.
    View in: PubMed
    Score: 0.006
  7. Regulation of nuclear oncogenes expressed in lung cancer cell lines. J Cell Biochem Suppl. 1996; 24:218-27.
    View in: PubMed
    Score: 0.005
  8. HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer. Mol Cancer Res. 2015 May; 13(5):809-18.
    View in: PubMed
    Score: 0.005
  9. The molecular biology of lung cancer: application to early detection and prevention. Oncology (Williston Park). 1993 Jun; 7(6):19-26; discussion 31-2, 37.
    View in: PubMed
    Score: 0.004
  10. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012 Dec; 130(12):1608-11.
    View in: PubMed
    Score: 0.004
  11. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res. 2011 May 01; 17(9):2863-73.
    View in: PubMed
    Score: 0.004
  12. Mortality in the randomized, controlled lung intergroup trial of isotretinoin. Cancer Prev Res (Phila). 2010 Jun; 3(6):738-44.
    View in: PubMed
    Score: 0.003
  13. High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009 Jan; 2(1):22-6.
    View in: PubMed
    Score: 0.003
  14. Clinical model of cost of bladder cancer in the elderly. Urology. 2008 Mar; 71(3):519-25.
    View in: PubMed
    Score: 0.003
  15. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007 May 20; 25(15):1974-8.
    View in: PubMed
    Score: 0.003
  16. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006 Sep; 68(3):549-53.
    View in: PubMed
    Score: 0.003
  17. Comparative outcomes of bladder cancer. Obstet Gynecol. 2006 Jul; 108(1):169-75.
    View in: PubMed
    Score: 0.003
  18. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Ann Thorac Surg. 2003 Oct; 76(4):1001-7; discussion 1007-8.
    View in: PubMed
    Score: 0.002
  19. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999 Oct 28; 18(44):6063-70.
    View in: PubMed
    Score: 0.002
  20. Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. Hum Pathol. 1999 Mar; 30(3):257-62.
    View in: PubMed
    Score: 0.002
  21. Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin. J Natl Cancer Inst. 1999 Jan 20; 91(2):135-43.
    View in: PubMed
    Score: 0.002
  22. Molecular characterization of adenocarcinoma of the cervix. Gynecol Oncol. 1997 Feb; 64(2):242-51.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.